JP2002530354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002530354A5 JP2002530354A5 JP2000583562A JP2000583562A JP2002530354A5 JP 2002530354 A5 JP2002530354 A5 JP 2002530354A5 JP 2000583562 A JP2000583562 A JP 2000583562A JP 2000583562 A JP2000583562 A JP 2000583562A JP 2002530354 A5 JP2002530354 A5 JP 2002530354A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antibody specific
- patients
- transplantation
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 7
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 229960004669 basiliximab Drugs 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 3
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 3
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 229940046731 calcineurin inhibitors Drugs 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940063121 neoral Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9825632.4A GB9825632D0 (en) | 1998-11-23 | 1998-11-23 | Organic compounds |
| GB9825632.4 | 1998-11-23 | ||
| PCT/EP1999/008988 WO2000030679A1 (en) | 1998-11-23 | 1999-11-22 | Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002530354A JP2002530354A (ja) | 2002-09-17 |
| JP2002530354A5 true JP2002530354A5 (https=) | 2007-01-11 |
Family
ID=10842889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000583562A Pending JP2002530354A (ja) | 1998-11-23 | 1999-11-22 | 移植の拒絶反応の出現の処置に使用するためのｃｄ２５結合分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20010041179A1 (https=) |
| EP (1) | EP1131098A1 (https=) |
| JP (1) | JP2002530354A (https=) |
| AU (1) | AU1384600A (https=) |
| GB (1) | GB9825632D0 (https=) |
| WO (1) | WO2000030679A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| US8252126B2 (en) * | 2004-05-06 | 2012-08-28 | Global Advanced Metals, Usa, Inc. | Sputter targets and methods of forming same by rotary axial forging |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| EP1208847B8 (en) * | 1996-07-30 | 2007-02-14 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
-
1998
- 1998-11-23 GB GBGB9825632.4A patent/GB9825632D0/en not_active Ceased
-
1999
- 1999-11-22 JP JP2000583562A patent/JP2002530354A/ja active Pending
- 1999-11-22 WO PCT/EP1999/008988 patent/WO2000030679A1/en not_active Ceased
- 1999-11-22 EP EP99972545A patent/EP1131098A1/en not_active Withdrawn
- 1999-11-22 AU AU13846/00A patent/AU1384600A/en not_active Abandoned
-
2001
- 2001-05-22 US US09/862,212 patent/US20010041179A1/en not_active Abandoned
-
2008
- 2008-07-28 US US12/180,660 patent/US20080286281A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nashan | Review of the proliferation inhibitor everolimus | |
| US9486445B2 (en) | Combination therapy for proliferative disorders | |
| US8633230B2 (en) | Viral hepatitis treatment | |
| Post et al. | Immunosuppression in liver transplantation | |
| Hernández et al. | Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus | |
| JPH0373158A (ja) | 哺乳動物に対する臓器又は組織の移植の拒絶を禁止する組成物 | |
| JP2009522371A5 (https=) | ||
| US20080286281A1 (en) | Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation | |
| US8435520B2 (en) | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections | |
| Kahan | Sirolimus-based immunosuppression: present state of the art | |
| JP2002530354A5 (https=) | ||
| JP2008520682A (ja) | ヒストンデアセチラーゼ阻害剤およびその使用方法 | |
| US20120329779A1 (en) | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias | |
| JP6878418B2 (ja) | 移植片拒絶反応の処置方法 | |
| WO2000038694A1 (en) | Medicinal compositions for treating osseous lesion in multiple myeloma | |
| GB2185886A (en) | Immunosuppressant agents containing ergot derivatives | |
| EP0372541A1 (en) | Method for imparting immunosuppression | |
| NL2022291B1 (en) | Compound for Use in Treatment and Prevention of Type I Diabetes | |
| Abrams et al. | Role of tacrolimus prolonged release in the prevention of allograft rejection | |
| WO2020160813A1 (en) | Method of treatment and pharmaceutical dosage form | |
| CN117224519A (zh) | L-犬尿氨酸作为一种免疫调节剂在器官移植中的应用 | |
| Becker et al. | Improved renal function of an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow-up of the Zeus Trial: 1757 | |
| Suddle et al. | Improved Short and Medium Term Renal Outcomes in Patients with Pre-Existing Renal Dysfunction Undergoing Liver Transplantation after Induction Therapy with Daclizumab: Results of a Single Centre Study.: Abstract# P-223 | |
| Nomany et al. | Kidney Transplantation (KT)–Current Management and Outcome |